<code id='4E25F87437'></code><style id='4E25F87437'></style>
    • <acronym id='4E25F87437'></acronym>
      <center id='4E25F87437'><center id='4E25F87437'><tfoot id='4E25F87437'></tfoot></center><abbr id='4E25F87437'><dir id='4E25F87437'><tfoot id='4E25F87437'></tfoot><noframes id='4E25F87437'>

    • <optgroup id='4E25F87437'><strike id='4E25F87437'><sup id='4E25F87437'></sup></strike><code id='4E25F87437'></code></optgroup>
        1. <b id='4E25F87437'><label id='4E25F87437'><select id='4E25F87437'><dt id='4E25F87437'><span id='4E25F87437'></span></dt></select></label></b><u id='4E25F87437'></u>
          <i id='4E25F87437'><strike id='4E25F87437'><tt id='4E25F87437'><pre id='4E25F87437'></pre></tt></strike></i>

          leisure time

          leisure time

          author:fashion    Page View:4634
          foreign-trained health professionals
          Adobe

          The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

          The American Hospital Association, the industry’s main lobbying group, told STAT it is “not commenting on this issue right now.” The American Medical Association had no comment and deferred to other physician trade groups. The Federation of American Hospitals offered no statement.

          advertisement

          The American Health Care Association, which lobbies on behalf of nursing homes, did not comment on the list of 10 drugs or Medicare’s negotiating power. But it said in a statement that “many nursing home residents have multiple chronic conditions that require several medications, so any efforts at reducing their out-of-pocket costs would be welcome.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more
          Overprescribed: High cost isn't America's only drug problem
          Overprescribed: High cost isn't America's only drug problem

          JulioCortez/APThepharmaceuticalindustryhasfollowedabrillianttwo-prongedstrategytomaximizeitsprofits:

          read more
          State Dept. review finds Biden bears some blame for Afghanistan failures
          State Dept. review finds Biden bears some blame for Afghanistan failures

          3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

          read more

          The lessons of Aduhelm, an Alzheimer's drug that was not to be

          StevenSenn/APAduhelm,apioneeringtreatmentforAlzheimer’sdiseasethatcollapsedundercorporatemistakesand